Study finds GI bleeding rare outside of ICU, regardless of whether or not patients receive medication

NewsGuard 100/100 Score

Over the last several decades, the prophylactic use of acid-suppressive medications to help prevent gastrointestinal bleeding (GI) in hospitalized patients has increased significantly, with some studies estimating that as many as 40 to 70 percent of all medical inpatients are given these drugs at some point during their hospitalization.

But, for patients who are not critically ill, the actual incidence of GI bleeding has not been well investigated.

Now, a study led by researchers at Beth Israel Deaconess Medical Center (BIDMC) and reported in today's on-line issue of The Archives of Internal Medicine finds that, outside of the intensive care unit (ICU), GI bleeding is rare, regardless of whether or not patients receive medication. And, say the authors, given that acid suppressive drugs have been associated with such complications as pneumonia and Clostridium difficile infections, these new findings suggest that, for the average hospital inpatient, the risks of acid suppressive agents may outweigh the benefits.

"The routine practice of prescribing these medications originated in the intensive care unit," says lead author Shoshana Herzig, MD, MPH, a physician in the Division of General Medicine and Primary Care at BIDMC and Instructor in Medicine at Harvard Medical School. "Because ICU patients are prone to stress ulceration [the erosion of gastric lining to the point of ulceration and sometimes bleeding] doctors began using acid suppressive drugs, such as proton pump inhibitor and histamine-2 receptor antagonists, as a prophylactic measure."

This regimen has proven highly effective in preventing ICU patients from developing gastric bleeding. But, as Herzig explains, over time, the routine also came into widespread use outside of the ICU, such that a majority of medical inpatients were also prescribed acid suppressive drugs during their hospital stay.

"In addition to the financial cost incurred by this practice, several recent studies have deomonstrated increased risk of infection associated with the use of acid-suppressive medication in hospitalized patients," the authors write in their paper. They, therefore, decided to determine the actual incidence of GI bleeding in non-ICU patients.

In their study, the authors examined a large cohort of 79,287 patients admitted to BIDMC between January 2004 and December 2007. Using a research method known as propensity score matching, they were able to control for such factors as age, gender, concurrent medication use and comorbid medical conditions. They found that GI bleeding in non-ICU patients occurred in only .29 percent of admissions.

"While the use of acid suppressive medication was indeed protective -- resulting in a 37 percent reduction in the risk of bleeding -- given the very low incidence of this complication, we determined that 770 patients would need to be treated with acid-suppressive medication to prevent a single episode of GI bleeding," Herzig explains.

"We know from other studies that the initiation of acid-suppressive medications also carries with it the risks of inappropriate continuation at the time of hospital discharge and the risks of drug-drug interactions," she adds. "Our findings lend further support to existing guidelines that suggest that acid-suppressive medications should not be used to prevent nosocomial bleeding in hospital patients outside the ICU. We hope that this research will help to further curb the inappropriate use of this class of medications."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Expanding research and clinical options for children with cancer